Activities of Michèle RIVASI related to 2021/2154(DEC)
Shadow reports (1)
REPORT on discharge in respect of the implementation of the budget of the Innovative Medicines Initiative 2 Joint Undertaking (now the Innovative Health Initiative Joint Undertaking) for the financial year 2020
Amendments (3)
Amendment 5 #
Motion for a resolution
Paragraph 6
Paragraph 6
6. Notes from the Court’s report that the IMI2 Joint Undertaking experiences long project durations due to the nature of its research and that this situation is an example of varying degrees of achievement of contribution targets set by the Joint Undertakings’ regulations in relation to Horizon 2020 activities, and that this presents the risk that the level of administrative resources needed to manage the Joint Undertaking’s funds in a timely manner, may not be sufficient, due to an increasing number of projects from multiple Multiannual Financial Framework programmes being implemented simultaneously; invites the IMI2 Joint Undertaking to review its organisational structure and staffing needs in order to ensure business continuity in periods of significantly increased workflows;
Amendment 8 #
Motion for a resolution
Paragraph 9
Paragraph 9
9. Notes that the IMI2 Joint Undertaking launched a fast-track call for proposals on coronavirus treatments and diagnostics, resulting in 8 projects; notes, moreover, the launch of three additional calls for proposals featuring topics on rare diseases, infectious diseases, cancer, neurodegenerative diseases and autoimmune diseases; notes, furthermore, the signing of 19 new grant agreements for projects with a total combined budget of over EUR 380 000 000, bringing the total IMI2 Joint Undertaking’s portfolio to 167 projects; notes that the new projects focus on cancer, diabetes, obesity, digital health, artificial intelligence, advanced therapies, drug discovery, and environmental issues; recalls that by selecting commercially interesting research topics for the pharmaceutical industry (such as diabetes or obesity) the IMI2 Joint Undertaking is not meeting the goals that justified its creation, namely improving the development and availability of health technologies for unmet medical needs; thus, considers that the interim evaluation of IMI2 Joint Undertaking realised in 2017 by the Commission and concluding that the added value of IMI2 Joint Undertaking for patients and for society in general is difficult to demonstrate is still valid;
Amendment 9 #
Motion for a resolution
Paragraph 11
Paragraph 11
11. Notes that several new tools and processes generated by IMI2 Joint Undertaking projects have been implemented by the industry participants (examples of such implementation are animal models, standards, biomarkers, standard operating procedures, use of screening platforms, clinical trial networks, etc.). Data also shows that there were 176 implementation results in IMI2 Joint Undertaking (versus a target of 50) and 482 implementation results for the IMI Joint Undertaking and IMI2 Joint Undertaking programmes considered together; notes, in addition, that 60 % of the projects involve patient organisations and healthcare professionals' associations as consortium partners, members of advisory boards, members of stakeholder groups etc., and that this trend has remained stable during the course of the IMI2 Joint Undertaking programme; is concerned however that IMI2 Joint Undertaking projects still fail to guarantee affordability, accessibility and availability of publicly funded research results; calls in this regard the IMI2 Joint Undertaking successor Innovative Health Initiative Joint Undertaking to introduce immediately new requirements, according to which all beneficiaries of the Union public funding for research and innovation for treatment, prevention or diagnosis shall commit to access, effectiveness, affordability and availability principles;